Abstract

Cervical cancer remains a major global health concern, with early detection and tailored treatment critical to improving patient outcomes. Recent advances in biomarker research have revolutionized the diagnosis, prognosis, and management of this disease, shifting the paradigm from generalized approaches to precision medicine. This article explores the role of biomarkers—molecular, genetic, and protein-based indicators—in enhancing the accuracy of cervical cancer detection, predicting disease progression, and guiding personalized therapeutic strategies. By analyzing key biomarkers such as HPV-related proteins, microRNAs, and DNA methylation patterns, the article highlights their transformative potential. It also evaluates their clinical utility based on current research and implementation, emphasizing how these tools could reduce mortality rates and optimize treatment efficacy. The findings suggest that biomarkers are poised to redefine cervical cancer care, though challenges in standardization and accessibility remain.